Prostate Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Olaparib Monotherapy for Advanced Prostate Cancer With Mutations: TAPUR Update
Darolutamide Plus ADT for Nonmetastatic Prostate Cancer: Final Update From ARAMIS
Early Results With Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer
AACR COVID-19: Hormonal Therapy and Severe Virus-Related Outcomes in Prostate Cancer
Leuprolide Plus Apalutamide as Neoadjuvant Therapy for Prostate Cancer
AACR COVID-19: Recent Trends in Screening for Prostate Cancer
Updated AUA, ASTRO, and SUO Guideline for Management of Advanced Prostate Cancer
Circulating Tumor DNA Analyses in Metastatic Castration-Resistant Prostate Cancer
AACR II: Pain Management in Veterans With Metastatic Castration-Resistant Prostate Cancer
Can Findings on PSMA PET/CT Alter Management in Recurrent Prostate Cancer?
Do Men Treated With Enzalutamide for Prostate Cancer PROSPER? Final Survival Results
PDK4 Gene May Serve as Prognostic Marker in Prostate Cancer
Bipolar Androgen Therapy in Metastatic Castration-Resistant Prostate Cancer
SPARTAN Final Results on Apalutamide in Castration-Resistant Prostate Cancer
Resensitization of Prostate Cancer With Bipolar Androgen Therapy
AACR II: Is Grape Seed Extract of Benefit to Men With Prostate Cancer?
AACR II: Therapeutic Benefits of Yoga in Men Treated With Prostatectomy
Bridging the Racial Gap: Underrepresentation of Minorities in Prostate Clinical Trials
ASCO20: Genetic Profiling to Guide Targeted Screening for Prostate Cancer
ASCO20: Phase I Trial of ARV-110 for Metastatic Castration-Resistant Prostate Cancer
Targeting Metabolic Pathway in Treating Aggressive Prostate Tumors
ASCO20: Cabozantinib Plus Atezolizumab for Castration-Resistant Prostate Cancer
ASCO20: Radical Prostatectomy After ADT for High-Risk Prostate Cancer
Radiotherapies Plus Androgen Deprivation After Surgery for High-Risk Prostate Cancer
ASCO20: Novel Imaging Modality Under Study in Biochemically Recurrent Prostate Cancer
ASCO20: LuPSMA Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
ASCO20: Predicting Outcomes in Metastatic Prostate Cancer With CTC Counts
ASCO20: HERO Trial Compares Relugolix and Leuprolide Acetate in Advanced Prostate Cancer
Chromosome 8 Haplotypes: Clinical Predictors of Risk for Hereditary Prostate Cancer?
Comparing Educational Sessions on Prostate Cancer Screening in Black Men
Olaparib Approved by FDA for Metastatic HRR-Mutated Castration-Resistant Prostate Cancer
Rucaparib Receives Accelerated Approval for Metastatic Castration-Resistant Prostate Cancer
Immunotherapy for Low–Mutational Burden Prostate Cancer
DDW 2020: One-Stop Multicancer Screening Center Program
Modeling Responses to Intermittent ADT in Patients With Advanced Prostate Cancer
AACR 2020: Adding Immunotherapy to Prostate Cancer Regimen in IMbassador250
Distinguishing Aggressive From Less-Threatening Types of Prostate Cancer
Comparing Robot-Assisted Radical Prostatectomy Approaches
Legislative Bill to Support Veterans With Prostate Cancer
ACC 2020: Risk of Cardiovascular Mortality With ADT in Prostate Cancer
Talazoparib in Metastatic Castration-Resistant Prostate Cancer
Real-World Use of Sipuleucel-T in Metastatic Prostate Cancer
Timing and Dosing Effects of Leuprolide Injections in Patients With Prostate Cancer
Recommendations for Prostate Cancer Radiotherapy During COVID-19 Pandemic
Pain Response With Different Therapies for Castration-Resistant Prostate Cancer
TAT 2020: IL-18 and Anticancer Immunity in Prostate Cancer
TAT 2020: CAR-Targeting L1CAM in Neuroendocrine Prostate Cancer
Combination Therapy for Enzalutamide-Resistant Prostate Cancer
GU Cancers Symposium 2020: Quality of Life in Men Treated for Advanced Prostate Cancer
GU Cancers Symposium 2020: Prostate Cancer Subtypes as Predictive Biomarker for Response to Chemotherapy
Fox Chase Researcher Receives Grant to Study Role of Cholesterol in Resistance to Prostate Cancer Treatment
GU Cancers Symposium 2020: Apalutamide and Time to Second Progression in Patients With Prostate Cancer
GU Cancers Symposium 2020: Use of Novel PET/CT Radiotracer in Staging High-Risk Prostate Cancer
GU Cancers Symposium 2020: Long-Term Outcomes With Hypofractionated Radiotherapy for Prostate Cancer
Using Individualized Pelvic Physical Therapy to Improve Surgical Complications


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.